Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab for sepsis in ICU patients
ACTRN12625001262493Phase 4Not yet recruiting
- Sponsor
- Dunedin Hospital Intensive Care Unit
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in sepsis and septic shock comparing Alirocumab plus standard of care with Standard of care (2 arms). Primary endpoint: Any change in ICU length of stay by days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
alirocumab
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on ACTRN12625001262493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001262493.